BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 20521318)

  • 1. Hyperprolactinemia associated with psychotropics--a review.
    Madhusoodanan S; Parida S; Jimenez C
    Hum Psychopharmacol; 2010; 25(4):281-97. PubMed ID: 20521318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of psychotropic-induced hyperprolactinemia.
    Marken PA; Haykal RF; Fisher JN
    Clin Pharm; 1992 Oct; 11(10):851-6. PubMed ID: 1341991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medication-induced hyperprolactinemia.
    Molitch ME
    Mayo Clin Proc; 2005 Aug; 80(8):1050-7. PubMed ID: 16092584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychotropic-induced hyperprolactinemia: a clinical review.
    Ajmal A; Joffe H; Nachtigall LB
    Psychosomatics; 2014; 55(1):29-36. PubMed ID: 24140188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].
    Besnard I; Auclair V; Callery G; Gabriel-Bordenave C; Roberge C
    Encephale; 2014 Feb; 40(1):86-94. PubMed ID: 23928066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suicide risk analysis among patients assigned to psychotropics and placebo.
    Khan A; Kolts RL; Brodhead AE; Krishnan KR; Brown WA
    Psychopharmacol Bull; 2006; 39(1):6-14. PubMed ID: 17065970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics.
    Chen CK; Huang YS; Ree SC; Hsiao CC
    Prog Neuropsychopharmacol Biol Psychiatry; 2010 Dec; 34(8):1495-9. PubMed ID: 20732372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose risperidone augmentation of antidepressants or anxiolytics is associated with hyperprolactinemia.
    Kopecek M; Bares M; Horacek J; Mohr P
    Neuro Endocrinol Lett; 2006 Dec; 27(6):803-6. PubMed ID: 17187006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipsychotic-induced hyperprolactinemia and sexual dysfunction.
    Compton MT; Miller AH
    Psychopharmacol Bull; 2002; 36(1):143-64. PubMed ID: 12397853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hyperprolactinemia in mentally ill patients].
    Carvalho MM; Góis C
    Acta Med Port; 2011; 24(6):1005-12. PubMed ID: 22713195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological hyperprolactinemia: a retrospective analysis of 501 hyperprolactinemia cases in primary care setting.
    García Cano AM; Rosillo M; Gómez Lozano A; Jiménez Mendiguchía L; Marchán Pinedo M; Rodríguez Torres A; Araujo-Castro M
    Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):3239-3246. PubMed ID: 37910184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Somatic side effects of psychopharmaceuticals].
    Schmidmeier R
    MMW Fortschr Med; 2006 Nov; 148(46):27-9. PubMed ID: 17615784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guidance on the treatment of antipsychotic-induced hyperprolactinemia when switching the antipsychotic is not an option.
    Rusgis MM; Alabbasi AY; Nelson LA
    Am J Health Syst Pharm; 2021 May; 78(10):862-871. PubMed ID: 33954421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugs for psychiatric disorders.
    Med Lett Drugs Ther; 1994 Oct; 36(933):89-96. PubMed ID: 7935156
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparing the Effectiveness and Safety of the Addition of and Switching to Aripiprazole for Resolving Antipsychotic-Induced Hyperprolactinemia: A Multicenter, Open-Label, Prospective Study.
    Yoon HW; Lee JS; Park SJ; Lee SK; Choi WJ; Kim TY; Hong CH; Seok JH; Park IH; Son SJ; Roh D; Kim BR; Lee BO
    Clin Neuropharmacol; 2016; 39(6):288-294. PubMed ID: 27438182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use and tolerability of newer antipsychotics and antidepressants: a chart review in a paediatric setting.
    Alacqua M; Trifirò G; Arcoraci V; Germanò E; Magazù A; Calarese T; Di Vita G; Gagliano C; Spina E
    Pharm World Sci; 2008 Jan; 30(1):44-50. PubMed ID: 17588130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching female schizophrenic patients to quetiapine from conventional antipsychotic drugs: effects on hyperprolactinemia.
    Nakajima M; Terao T; Iwata N; Nakamura J
    Pharmacopsychiatry; 2005 Jan; 38(1):17-9. PubMed ID: 15706461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychotropic drug use in older people with mental illness with particular reference to antipsychotics: a systematic study of tolerability and use in different diagnostic groups.
    Curran S; Turner D; Musa S; Wattis J
    Int J Geriatr Psychiatry; 2005 Sep; 20(9):842-7. PubMed ID: 16116576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.
    Haddad PM; Wieck A
    Drugs; 2004; 64(20):2291-314. PubMed ID: 15456328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.